about
Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.A public health approach to the prevention of inhibitors in hemophilia.National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meetingGender, race and diet affect platelet function tests in normal subjects, contributing to a high rate of abnormal results.Females with FVIII and FIX deficiency have reduced joint range of motionMutation analysis of a cohort of US patients with hemophilia B.Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutationsA study of prospective surveillance for inhibitors among persons with haemophilia in the United States.The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource.Utility of multiplex ligation-dependent probe amplification (MLPA) for hemophilia mutation screening.Game, set, match for factor VIII mismatch?Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia.Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening.Improving the performance of factor VIII inhibitor tests in hemophilia A.Laboratory tests for the diagnosis of thrombotic disorders.Impact of smoking during pregnancy on functional coagulation testingLaboratory testing for factor inhibitors.In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.Impact of inhibitors on hemophilia A mortality in the United States.The spectrum of haemostatic characteristics of women with unexplained menorrhagia.Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.Cluster of inhibitors among adult inpatients with haemophilia in a single institution.Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid.Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time.Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.Complications associated with carrier status among people with blood disorders: a commentary.Elevated factor VII as a risk factor for recurrent fetal loss. Relationship to factor VII gene polymorphisms.von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia.Confirmation of autosomal dominant transmission of the DiGeorge malformation complexThe beta fibrinogen gene G-455-A polymorphism is a risk factor for Legg-Perthes diseaseDistinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patientsReagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitorsPhenotypic and genotypic differences in factor XII between African Americans and CaucasiansAge and the prevalence of bleeding disorders in women with menorrhagiaReagent substitution in the chromogenic Bethesda assay for factor VIII inhibitors
P50
Q35248264-7F952E54-219B-4AC4-A415-7C6C3EE84F56Q35747998-6303B270-7B02-43F1-B857-0F8C00C0F1EAQ35755679-3E0A9494-EC67-497A-8736-A6DE1B04828AQ35770815-619BE3B8-FBA2-4A45-83F4-9F20552CAC1FQ35771219-FFD73BC0-697A-4958-B91A-147F0CD6843FQ35857102-CF1B7682-31AE-41DB-8585-671B3061752BQ35881803-FBEC87F8-DC05-411A-B2AF-50577C02F070Q35902290-F4FFCC6E-43AA-44B5-8E96-344C2DA976F6Q35902341-62EB5903-7E81-4961-9539-521B1F537123Q35906321-D0E2B352-A43A-4413-97EF-2EFBA215C43AQ36015787-E0CBB6B7-6396-4E37-A36E-CC5873261D09Q36136649-BE2059C5-79A8-4A55-A133-6D8A8BB502CDQ36274480-8A4A8B8F-503A-44B7-8EAB-B6E138F6D96BQ36477040-541DFFF1-4ADE-4894-B0DC-D9D74AB44185Q36643480-2387182E-C5BD-4C23-A9EC-6322D15D9B4FQ37163228-B9D6C11F-775B-49DD-A371-647A0087B895Q38206857-C6F1AF67-49AD-46D8-9CBB-BC5312380E20Q39463597-AA5ED6EE-574A-4ABC-89D9-A675D8528DABQ41524981-041A1BDF-FAA6-4529-9754-4D55D851922CQ45864578-3675F294-88E7-40AF-AD27-070903ABFEFDQ45870641-2445DAC8-9D91-4309-B9EF-C475512CEC7CQ45875598-2112D3E8-F1A8-4F02-AB28-66B4108857A3Q45883392-C903EE59-7237-4549-A280-B9970EAFAC49Q45886389-AB62EB5E-9B86-4845-BF87-05508B70D515Q49988033-0AD60239-8CCD-4AC6-B1A8-E6D2B24D8AEAQ51911737-769033AC-4223-4B85-9F5B-FE5BD2DDB9FDQ52046610-4B3C7F33-9D3B-4052-AD34-235B7C306762Q53327187-F5E48C94-6C79-453A-9B07-7F973B45F818Q58426333-D6B55724-B7FA-4EE9-8801-8B6639F48A85Q64134027-14B376E8-E635-49E4-B022-7698DC14FB9EQ64137049-2BCB58B3-4CD9-4342-9D5C-467AEB47B8E2Q64138087-D07FBFA3-217C-4704-BB2B-D7CA319C049FQ80537640-E78671D9-79EE-4720-9C02-4F226F7A99B6Q81212700-AA1C15BD-FAA6-4F49-9D3C-06A17158FD19Q92271543-CD05EF83-4EEA-43B8-B581-4AC645E778B6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Connie H. Miller
@ast
Connie H. Miller
@en
Connie H. Miller
@es
Connie H. Miller
@nl
Connie H. Miller
@sl
type
label
Connie H. Miller
@ast
Connie H. Miller
@en
Connie H. Miller
@es
Connie H. Miller
@nl
Connie H. Miller
@sl
prefLabel
Connie H. Miller
@ast
Connie H. Miller
@en
Connie H. Miller
@es
Connie H. Miller
@nl
Connie H. Miller
@sl
P106
P1153
7406254075
P31
P496
0000-0002-3989-7973